Kidney International Reports最新文献

Focusing on Older Adults With Antineutrophil Cytoplasmic Autoantibody–Negative Pauci-Immune Glomerulonephritis 针对抗中性粒细胞胞浆自身抗体阴性的老年包囊免疫肾小球肾炎

IF 5.7 2区医学

Kidney International Reports Pub Date : 2025-06-01 DOI: 10.1016/j.ekir.2025.03.034

Henry H.L. Wu , Rajkumar Chinnadurai

引用次数: 0

Temporal Changes in Blood Metabolome: Understanding Biochemical Changes in Hemodialysis Patients 血液代谢组的时间变化：了解血液透析患者的生化变化

IF 5.7 2区医学

Kidney International Reports Pub Date : 2025-06-01 DOI: 10.1016/j.ekir.2025.04.048

Shereen M. Aleidi , Anas Abdel Rahman

引用次数: 0

Public Data in Nephrology: A Researcher’s Roadmap 肾脏病学的公共数据：研究人员的路线图

IF 5.7 2区医学

Kidney International Reports Pub Date : 2025-06-01 DOI: 10.1016/j.ekir.2025.04.010

Eoin Daniel O’Sullivan , Monica Suet Ying Ng , Venkat Vangaveti , Nicholas Matigian , Andrew John Mallett

引用次数: 0

Systematic Review of Patient and Caregiver Involvement in CKD Research CKD研究中患者和护理人员参与的系统综述

IF 5.7 2区医学

Kidney International Reports Pub Date : 2025-06-01 DOI: 10.1016/j.ekir.2025.03.018

Talia Gutman , Dale Coghlan , Jonathan C. Craig , Chandana Guha , Allison Jaure , Shilpanjali Jesudason , Adeera Levin , David M. White , Javier Recabarren Silva , Anita van Zwieten , David Tunnicliffe , Andrea K. Viecelli , Germaine Wong , Armando Teixeira-Pinto , Siah Kim , Stephen McDonald , Carmel M. Hawley , Nicole Scholes-Robertson

{"title":"Systematic Review of Patient and Caregiver Involvement in CKD Research","authors":"Talia Gutman , Dale Coghlan , Jonathan C. Craig , Chandana Guha , Allison Jaure , Shilpanjali Jesudason , Adeera Levin , David M. White , Javier Recabarren Silva , Anita van Zwieten , David Tunnicliffe , Andrea K. Viecelli , Germaine Wong , Armando Teixeira-Pinto , Siah Kim , Stephen McDonald , Carmel M. Hawley , Nicole Scholes-Robertson","doi":"10.1016/j.ekir.2025.03.018","DOIUrl":"10.1016/j.ekir.2025.03.018","url":null,"abstract":"<div><h3>Introduction</h3><div>Limited consumer involvement in chronic kidney disease (CKD) research may reduce its relevance, impact, and transferability into practice and policy. We aimed to describe the current landscape of consumer (patients with CKD and caregivers) involvement in published CKD research.</div></div><div><h3>Methods</h3><div>Electronic databases were searched to August 2023. Articles describing consumer involvement in CKD research were eligible. All text were imported into NVivo for line-by-line coding using descriptive synthesis of these domains: defining involvement, purpose of involvement, selection, stages of the research, resources, and evaluation.</div></div><div><h3>Results</h3><div>We included 106 articles that involved over 4500 consumers from 15 countries. Eighty-two articles (77%) defined consumer involvement, using 8 different terms. Forty-three articles (41%) addressed reasons for involving consumers in research. Consumers were predominantly identified through clinical or patient networks based on demographic or clinical characteristics. Those involved at higher levels (e.g., coresearcher/patient partner) often had medical or academic training. Consumers were rarely drivers or commissioners of research (<em>n</em> = 6, 6%) and were most likely to be involved as informants (<em>n</em> = 81, 76%) with limited decision-making power. Most articles described consumer involvement in priority setting (<em>n</em> = 48, 45%) and research design (<em>n</em> = 57, 53%) with less evidence of involvement in implementation (<em>n</em> = 28, 26%) and evaluation (<em>n</em> = 24, 22%). Barriers included limited resources (i.e., financial, logistical, or training) and the need for tailored solutions continue to exist. Consumer involvement resulted in increased recruitment and retention, richer data, and more useful outputs for end users.</div></div><div><h3>Conclusions</h3><div>Consumers were mostly involved in discrete activities with limited decision-making power. Increasing financial, logistical, and training resources for consumers may support more meaningful involvement. Ongoing evaluation of processes or impacts of consumer involvement, including consistent reporting, is needed to strengthen evidence and practice in CKD research.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 6","pages":"Pages 1657-1672"},"PeriodicalIF":5.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144223026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Positive Anti–Glomerular Basement Membrane and Proteinase 3–Antineutrophil Cytoplasmic Autoantibody in Infective Endocarditis-Associated Glomerulonephritis: A Diagnostic Challenge 抗肾小球基底膜和蛋白酶3 -抗中性粒细胞胞浆自身抗体阳性在感染性心内膜炎相关性肾小球肾炎：一个诊断挑战

IF 5.7 2区医学

Kidney International Reports Pub Date : 2025-06-01 DOI: 10.1016/j.ekir.2025.03.030

Susan J. Thanabalasingam , Ronald A. Booth , Mark Canney , Nataliya Milman , Adrian Agostino , David Massicotte-Azarniouch

引用次数: 0

Obinutuzumab for Relapsing Myeloperoxidase-Antineutrophil Cytoplasmic Autoantibody–Associated Glomerulonephritis Obinutuzumab治疗复发性髓过氧化物酶-抗中性粒细胞胞浆自身抗体相关性肾小球肾炎

IF 5.7 2区医学

Kidney International Reports Pub Date : 2025-06-01 DOI: 10.1016/j.ekir.2025.04.026

Michael Cammarata , Brendan Denvir , Aditi Singh , Bangchen Wang , Brendan Antiochos , Duvuru Geetha

引用次数: 0

Prospective Study of the Association Between Frailty and Health Care Utilization in Patients With Advanced CKD 晚期CKD患者虚弱与医疗保健利用关系的前瞻性研究

IF 5.7 2区医学

Kidney International Reports Pub Date : 2025-06-01 DOI: 10.1016/j.ekir.2025.03.032

Alice L. Kennard , Alice M. Richardson , Suzanne Rainsford , Kelly L. Hamilton , Nicholas J. Glasgow , Kate L. Pumpa , Angela M. Douglas , Girish S. Talaulikar

{"title":"Prospective Study of the Association Between Frailty and Health Care Utilization in Patients With Advanced CKD","authors":"Alice L. Kennard , Alice M. Richardson , Suzanne Rainsford , Kelly L. Hamilton , Nicholas J. Glasgow , Kate L. Pumpa , Angela M. Douglas , Girish S. Talaulikar","doi":"10.1016/j.ekir.2025.03.032","DOIUrl":"10.1016/j.ekir.2025.03.032","url":null,"abstract":"<div><h3>Introduction</h3><div>Frailty likely contributes to disproportionate health care utilization among people living with chronic kidney disease (CKD) and undergoing hemodialysis (HD); but this is poorly captured in nephrology clinical and research practice. We examined Fried frailty phenotype among participants with CKD or on HD and explored associations with health care utilization. We examined frailty transitions in relation to hospitalization.</div></div><div><h3>Methods</h3><div>We conducted a prospective observational single-center study of patients with advanced CKD or undergoing HD. Frailty was assessed at baseline, 6 and 12 months. Demographic and clinical data, including comorbid burden, disability, and laboratory parameters were recorded. Data linkage with tertiary hospital captured emergency department (ED) presentations, hospital admissions, and days of hospital stay, excluding admissions for maintenance HD. Negative binomial regression was used to model health care utilization patterns. Frailty progression over study follow-up was described using Cox proportional hazards modelling.</div></div><div><h3>Results</h3><div>Among 256 participants, frailty (36.3%) and prefrailty (46.5%) were highly prevalent. Frailty independently predicted ED presentation (incidence rate ratio [IRR]: 1.25, 95% confidence interval [CI]: 1.09–1.43), hospitalization (IRR: 1.22, 95% CI: 1.08–1.37), and total days of hospitalization (IRR: 1.29, 95% CI: 1.06–1.57) independent of demographics, comorbidity, disability, and inflammation. The median occurrence of hospitalization events was 152 days (interquartile range [IQR]: 44–251) after enrolment, suggesting a window of opportunity where frailty recognition might prompt targeted intervention to prevent frailty-related sequelae. Frailty was highly dynamic; frailty progression was not associated with hospitalization or length of stay.</div></div><div><h3>Conclusion</h3><div>Frailty is a major contributor to excess health care utilization among people with kidney disease. Recognition of the prognostic implications of frailty might allow timely introduction of interventions to improve patient outcomes.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 6","pages":"Pages 1694-1710"},"PeriodicalIF":5.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144222948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dotinurad Treatment for Patients With Hyperuricemia Complicating CKD 高尿酸血症合并CKD患者的多替尼治疗

IF 5.7 2区医学

Kidney International Reports Pub Date : 2025-06-01 DOI: 10.1016/j.ekir.2025.03.047

Katsuyuki Tanabe , Tomokazu Nunoue , Naoki Itabashi , Akihiro Katayama , Akihiko Nakamura , Hiroyuki Ohbayashi , Yasuhiro Onishi , Kyoko Watanabe , Keisuke Maruyama , Takeshi Hosoya , Shinichi Okada , Jun Wada , DTN-CKD Investigators

{"title":"Dotinurad Treatment for Patients With Hyperuricemia Complicating CKD","authors":"Katsuyuki Tanabe , Tomokazu Nunoue , Naoki Itabashi , Akihiro Katayama , Akihiko Nakamura , Hiroyuki Ohbayashi , Yasuhiro Onishi , Kyoko Watanabe , Keisuke Maruyama , Takeshi Hosoya , Shinichi Okada , Jun Wada , DTN-CKD Investigators","doi":"10.1016/j.ekir.2025.03.047","DOIUrl":"10.1016/j.ekir.2025.03.047","url":null,"abstract":"<div><h3>Introduction</h3><div>The management of hyperuricemia is important to reduce cardiovascular risk and the progression of renal injury in chronic kidney disease (CKD). This study aimed to assess the efficacy and safety of dotinurad, a novel urate transporter-1 inhibitor, in patients with hyperuricemia and CKD.</div></div><div><h3>Methods</h3><div>In a nonrandomized, parallel interventional study, patients were grouped based on their estimated glomerular filtration rate (eGFR) at baseline. The starting dotinurad dose was 0.5 mg/d and titrated to a final dose of 2 mg/d to 4 mg/d. The primary end point was the noninferiority of the change in serum uric acid (UA) levels between the G1/G2 and G3/G4 groups at week 24. The main secondary end points were changes in eGFR and UA clearance-to-creatinine clearance ratio (C<sub>UA</sub>/C<sub>Cr</sub>). Reported adverse events were also investigated.</div></div><div><h3>Results</h3><div>Ninety-eight patients continued the dose titration. The mean percentage reduction in serum UA level at week 24 were 47.2% and 42.8% for the G1/G2 and G3/G4 groups, respectively; the between-group difference was −4.3% (95% confidence interval [CI], −9.5% to 0.9%, noninferiority <em>P</em> = 0.0321), validating the noninferiority of treatment in the G3/G4 group to the G1/G2 group. eGFR tended to increase slightly through to week 24, suggesting that spontaneous eGFR decline was counteracted. Mean C<sub>UA</sub>/C<sub>Cr</sub> generally increased over time from week 4 to week 24. No new safety issues of particular concern were identified; and there were no marked changes in urinary pH.</div></div><div><h3>Conclusion</h3><div>Dotinurad therapy may be well-tolerated in patients with hyperuricemia and may have efficacy comparable with existing standard treatment in patients with CKD stages G3/G4. Randomized controlled trials in larger patient groups are needed.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 6","pages":"Pages 1711-1720"},"PeriodicalIF":5.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144222949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reversible Glomerular Thrombotic Microangiopathy Associated With Nintedanib in a Kidney Transplant Recipient 肾移植受者与尼达尼布相关的可逆性肾小球血栓性微血管病

IF 5.7 2区医学

Kidney International Reports Pub Date : 2025-06-01 DOI: 10.1016/j.ekir.2025.04.015

Gabriel Ouellet , Cécile Picard , Maud Rabeyrin , Fanny Buron , François Lestelle , Julie Bellière , Alice Koenig , Olivier Thaunat , Emmanuel Morelon , Xavier Charmetant

引用次数: 0

Update on Acute Tubulointerstitial Nephritis: Clinical Features, Immunologic Insights, and Diagnostic and Treatment Approaches 急性肾小管间质性肾炎的最新进展：临床特征、免疫学见解、诊断和治疗方法

IF 5.7 2区医学

Kidney International Reports Pub Date : 2025-06-01 DOI: 10.1016/j.ekir.2025.03.050

Tuncay Sahutoglu , Mark A. Perazella

{"title":"Update on Acute Tubulointerstitial Nephritis: Clinical Features, Immunologic Insights, and Diagnostic and Treatment Approaches","authors":"Tuncay Sahutoglu , Mark A. Perazella","doi":"10.1016/j.ekir.2025.03.050","DOIUrl":"10.1016/j.ekir.2025.03.050","url":null,"abstract":"<div><div>Acute tubulointerstitial nephritis (ATIN) is a leading cause of acute kidney injury (AKI) and acute kidney disease. It is characterized by interstitial inflammation and tubular injury, often triggered by medications, infections, or autoimmune disorders. Prompt diagnosis and treatment are crucial to prevent irreversible kidney damage; however, nonspecific clinical and laboratory findings pose diagnostic challenges. Although kidney biopsy remains the gold standard, its invasive nature and potential complications necessitate the exploration of alternative noninvasive strategies.</div><div>Emerging biomarkers offer promising noninvasive tools for diagnosing ATIN and differentiating it from other causes of AKI and acute kidney disease. Biomarker applications, as an alternative, are viewed through the lens of distinct immune reaction subtypes, including variations in type IV hypersensitivity mechanisms. Biomarkers such as urinary CXC chemokine ligand (CXCL)9 and cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-9 reflect T-cell polarization and specific inflammatory pathways, shedding light on T helper (Th)1- and Th2-mediated immune responses. Among these, the urinary CXCL9-to-creatinine ratio demonstrates high sensitivity and specificity, with well-defined thresholds guiding clinical decisions. Urinary retinol-binding protein and serum C-reactive protein (CRP) have also been explored, particularly in immune checkpoint inhibitor (ICPI)-associated AKI. However, their nonspecificity and overlap with other AKI etiologies limit their utility in isolating ATIN-specific pathways.</div><div>This review highlights the need for integrating biomarker-based approaches with a broader understanding of immune heterogeneity and histologic correlation to improve diagnostic precision. Future studies should focus on validating biomarker panels that capture diverse inflammatory endotypes, enabling early diagnosis and personalized management. By acknowledging the complexity of immune reactions underlying ATIN, this approach aims to enhance clinical decision-making while minimizing the need for invasive diagnostics, ultimately improving patient outcomes.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 6","pages":"Pages 1643-1656"},"PeriodicalIF":5.7,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144223025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0